Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Journey through Pages: A Survey of \Plunging into Scholarly Universes\ - 2Gaza amputees struggle to rebuild lives as the enclave faces shortages of prosthetic limbs
- 3Damaged launch pad: How long before Russia can send astronauts to the ISS again?
- 4Motivational Travel Objections for History Buffs
- 5Pulsars to the extreme: Spinning dead stars found blasting radio signals from the 'edge of their magnetic reach'
- Deadly attack on kindergarten reported in Sudan
- Lebanese Shi’a party Amal competing, coordinating with Hezbollah, experts tell ‘Post’
- Cognizant Couture d: A Survey of \Moral Decisions and Sharp Looks\ Maintainable Style
- CDC changes kids' vaccine schedule, removing universal recommendation for some shots
- National health ranking puts Georgia near bottom of list. Here's why
- Trump says Cuba is 'ready to fall' after capture of Venezuela's Maduro
- Protest inspired by 'Gen Z' movement draws few young people in Mexico and many government critics
- UK, Canada, Germany, others condemn Israel's West Bank settlement plan
- Vote In favor of Your Favored Kind Of Vegetable
